San Diego-based Viking Therapeutics marked by itself as a significant competitor from the weight loss drug marketplace in February following revealing promising information from a mid-phase demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection and in March the